Diosmin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Diosmin: From Chronic Venous Insufficiency to Amenorrhea
One-Sentence Summary
Diosmin is a naturally occurring flavonoid glycoside with established use in Europe and Asia for chronic venous insufficiency and hemorrhoidal disease, though it carries no Singapore regulatory registration. The TxGNN model predicts it may be effective for Amenorrhea, with a prediction confidence of 99.42%. However, no clinical trials and no supporting publications currently exist for this specific indication, placing this prediction at the lowest evidence tier.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Chronic venous insufficiency / Hemorrhoidal disease (established global use; not registered in Singapore) |
| Predicted New Indication | Amenorrhea |
| TxGNN Prediction Score | 99.42% |
| Evidence Level | L5 |
| Singapore Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why Is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on known pharmacological information, Diosmin is a bioflavonoid with several vascular and anti-inflammatory effects: it increases venous tone by protecting norepinephrine from oxidative degradation, reduces capillary permeability by stabilising the endothelial glycocalyx, inhibits prostaglandin E2 and I2 synthesis to dampen vascular wall inflammation, and suppresses NF-κB-driven leukocyte adhesion. These properties underpin its established role in venous insufficiency management.
The predicted link to amenorrhea draws on a separate, weaker pharmacological feature: like many flavonoids, Diosmin possesses mild phytoestrogenic activity and can partially bind oestrogen receptors ER-α and ER-β. In theory, this could exert a modest modulatory effect on the hypothalamic-pituitary-ovarian (HPO) axis and menstrual cycle regulation.
In practice, however, this connection is highly speculative. Diosmin's phytoestrogenic potency is far lower than that of well-studied phytoestrogens such as soy isoflavones. Furthermore, amenorrhea is an aetiologically heterogeneous condition — causes range from central hypothalamic suppression and pituitary pathology to primary ovarian insufficiency and structural uterine abnormalities — making a single mechanistic bridge implausible without far more targeted data. The prediction is noted as biologically creative but pharmacologically unsubstantiated at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
Diosmin carries no Singapore HSA registration. No product authorisations are on record.
Safety Considerations
Please refer to the package insert for safety information.
Note: Safety data including key warnings, contraindications, and drug interaction records were not retrievable at the time this Evidence Pack was compiled. These represent blocking data gaps that must be resolved before any clinical evaluation can proceed.
Conclusion and Next Steps
Decision: Hold
Rationale: There is no clinical trial or published literature evidence connecting Diosmin to amenorrhea treatment, and the mechanistic hypothesis — based solely on weak phytoestrogenic receptor binding — is highly speculative and unvalidated in any preclinical or clinical model for this indication.
To proceed, the following is needed:
- Mechanism of action data — retrieve Diosmin's full MOA from DrugBank API (identified as High-severity data gap DG002) to confirm whether phytoestrogenic activity is sufficiently characterised to justify further investigation
- Safety package — obtain Singapore HSA package insert or equivalent regulatory document to resolve the Blocking data gap (DG001) before any clinical stage planning
- Amenorrhea subtype stratification — determine whether any subtype (hypothalamic, pituitary, ovarian, or uterine origin) presents a plausible mechanistic entry point for Diosmin's known biological activities
- Preclinical evidence generation — commission in vitro or animal studies assessing Diosmin's effect on HPO axis function or endometrial receptivity before advancing to clinical hypotheses
- Singapore registration pathway assessment — if evidence eventually supports this indication, map out HSA registration requirements given the drug's current zero-registration status in Singapore
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.